FVL, a common variant in the factor V gene resulting activated protein C resistance has a prevalence of 2 to 7 percent in most European populations and has been observed in 20 to 50 percent of patients with venous thromboembolic disease [13]. This evidence concerns the gene F5 and venous thromboembolism.